Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

25 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Screening and Treatment Program to Eliminate Hepatitis C in Egypt.
Waked I, Esmat G, Elsharkawy A, El-Serafy M, Abdel-Razek W, Ghalab R, Elshishiney G, Salah A, Abdel Megid S, Kabil K, El-Sayed MH, Dabbous H, El Shazly Y, Abo Sliman M, Abou Hashem K, Abdel Gawad S, El Nahas N, El Sobky A, El Sonbaty S, El Tabakh H, Emad E, Gemeah H, Hashem A, Hassany M, Hefnawy N, Hemida AN, Khadary A, Labib K, Mahmoud F, Mamoun S, Marei T, Mekky S, Meshref A, Othman A, Ragab O, Ramadan E, Rehan A, Saad T, Saeed R, Sharshar M, Shawky H, Shawky M, Shehata W, Soror H, Taha M, Talha M, Tealaab A, Zein M, Hashish A, Cordie A, Omar Y, Kamal E, Ammar I, AbdAlla M, El Akel W, Doss W, Zaid H. Waked I, et al. Among authors: el shazly y. N Engl J Med. 2020 Mar 19;382(12):1166-1174. doi: 10.1056/NEJMsr1912628. N Engl J Med. 2020. PMID: 32187475 No abstract available.
Real life Egyptian experience of efficacy and safety of Simeprevir/Sofosbuvir therapy in 6211 chronic HCV genotype IV infected patients.
Eletreby R, Elakel W, Said M, El Kassas M, Seif S, Elbaz T, El Raziky M, Abdel Rehim S, Zaky S, Fouad R, Gamal Eldeen H, Abdo M, Korany M, Yosry A, El Serafy M, El-Sayed MH, ElShazly Y, Waked I, Doss W, Esmat G. Eletreby R, et al. Liver Int. 2017 Apr;37(4):534-541. doi: 10.1111/liv.13266. Epub 2016 Nov 4. Liver Int. 2017. PMID: 27712017
Planning and prioritizing direct-acting antivirals treatment for HCV patients in countries with limited resources: Lessons from the Egyptian experience.
Elsharkawy A, El-Raziky M, El-Akel W, El-Saeed K, Eletreby R, Hassany M, El-Sayed MH, Kabil K, Ismail SA, El-Serafy M, Abdelaziz AO, Shaker MK, Yosry A, Doss W, El-Shazly Y, Esmat G, Waked I. Elsharkawy A, et al. Among authors: el sayed mh, el saeed k, el serafy m, el raziky m, el akel w, el shazly y. J Hepatol. 2018 Apr;68(4):691-698. doi: 10.1016/j.jhep.2017.11.034. Epub 2017 Dec 6. J Hepatol. 2018. PMID: 29223371
Spur-of-the-Moment Modification in National Treatment Policies Leads to a Surprising HCV Viral Suppression in All Treated Patients: Real-Life Egyptian Experience.
El Kassas M, Omran D, Elsaeed K, Alboraie M, Elakel W, El Tahan A, Abd El Latif Y, Nabeel MM, Korany M, Ezzat S, El-Serafy M, ElShazly Y, Doss W, Esmat G. El Kassas M, et al. J Interferon Cytokine Res. 2018 Feb;38(2):81-85. doi: 10.1089/jir.2017.0121. Epub 2018 Jan 22. J Interferon Cytokine Res. 2018. PMID: 29356573
High SVR rate following retreatment of non-sustained virological responders to sofosbuvir based anti-HCV therapies regardless of RAS testing: A real-life multicenter study.
Darweesh SK, Elsaeed K, Omar H, El Raziky M, Elakel W, Elserafy M, Ismail SA, Gomaa AA, Mehrez M, El Kassas M, Abdullah M, Shaker MK, Esmat G, El Shazly Y, Doss W, Waked I. Darweesh SK, et al. Among authors: el shazly y. Expert Rev Gastroenterol Hepatol. 2019 Sep;13(9):907-914. doi: 10.1080/17474124.2019.1629287. Epub 2019 Jun 23. Expert Rev Gastroenterol Hepatol. 2019. PMID: 31173527
Liver stiffness measurements and FIB-4 are predictors of response to sofosbuvir-based treatment regimens in 7256 chronic HCV patients.
Abdel Alem S, Elsharkawy A, El Akel W, Abdelaziz AO, Salama RM, El-Sayed MH, El Kassas M, Anees M, Shedeed M, Abdelsalam F, Ziada DH, El Shazly Y, El-Serafy M, Waked I, Esmat G, Doss W. Abdel Alem S, et al. Among authors: el shazly y. Expert Rev Gastroenterol Hepatol. 2019 Oct;13(10):1009-1016. doi: 10.1080/17474124.2019.1653183. Epub 2019 Aug 16. Expert Rev Gastroenterol Hepatol. 2019. PMID: 31418303
Sofosbuvir-containing regimens are safe and effective in the treatment of HCV patients with moderate to severe renal impairment.
Eletreby R, El-Serafy M, Anees M, Kasem G, Salama M, Elkhouly R, Hamdy M, Abdel Haleem H, Kamal E, Abdel-Razek W, Salama R, Elshenawy M, Shafeek A, Hassany M, El-Sayed MH, El-Shazly Y, Esmat G. Eletreby R, et al. Among authors: el shazly y. Liver Int. 2020 Apr;40(4):797-805. doi: 10.1111/liv.14299. Epub 2019 Dec 20. Liver Int. 2020. PMID: 31858694
25 results